AstraZeneca: Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Press/Media

Period30 Mar 2020

Media coverage

1

Media coverage

  • TitleAstraZeneca: Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date30/03/20
    PersonsRoxana Mehran,